Aim: Proton pump inhibitor (PPI) therapy has been shown to attenuate the antiplatelet effects of clopidogrel. The aim of this study was to compare the antiplatelet effects of cilostazol versus clopidogrel in patients co-administered a PPI. Methods: We enrolled PPI-naïve stented patients treated with standard clopidogrel and aspirin therapy for at least six months (n = 100). The patients were randomly assigned to receive either cilostazol at a dose of 100 mg twice daily (CILO group) or clopidogrel at a dose of 75 mg daily (CLPD group) in addition to lansoprazole (30 mg daily). The platelet aggregation (PA) determined using light transmittance aggregometry and the platelet reactivity index (PRI) obtained using a vasodilator-stimulated phosphoprotein phosphorylation assay were measured before randomization and at the 14-day follow-up visit. The primary endpoint was the PRI value at follow-up. Results: At follow-up, the CLPD group showed similar values of PRI as the CILO group (66.9±14.0% vs. 63.1±14.1%; mean difference: 3.9%; 95% confidence interval of difference: −1.7% to 9.4%; p=0.174). However, the 6 μg/mL collagen-and 0.5 mg/mL arachidonic acid-induced PA values in the CLPD group were higher than those observed in the CILO group (mean differences: 9.8% to 11.1%; all p values ＜0.001). CYP2C19 loss-of-function allele carriage was the major contributing factor associated with the PRI level in the absence of lansoprazole treatment (with a gene-dose effect); this association was not observed in the subjects receiving lansoprazole co-administration in the CLPD group. Conclusions: During lansoprazole co-administration, cilostazol treatment achieves a more favorable platelet function profile than clopidogrel therapy. The use of combination treatment with cilostazol and aspirin deserves further attention with respect to the management of stable stented patients requiring PPI co-administration. 
Introduction
Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin has been shown to reduce major cardiovascular events following percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS). However, the risk of gastrointestinal (GI) Park Y and Jung JM contributed equally to this work.
cilostazol compared with that of ADP P2Y12 receptor blockers and the findings of a previous report of healthy subjects showing relatively lower inhibitory effects of ADP-mediated platelet aggregation by cilostazol than with clopidogrel 18) may limit its clinical application in stented patients. Since cilostazol is also metabolized by the CYP2C19 enzyme 19) , the CYP2C19 genetic polymorphism and/or concomitant use of a PPI may influence its pharmacodynamic effect.
In the current study, we therefore evaluated the influence of lansoprazole administration on the effects of clopidogrel and compared the pharmacodynamic actions of cilostazol vs. clopidogrel treatment during PPI co-administration in patients with a history of coronary stenting.
bleeding under DAPT is increased two-to three-fold compared with that observed for aspirin alone 1, 2) . Therefore, guidelines and consensus documents recommend treatment with proton pump inhibitors (PPIs) in patients receiving DAPT, particularly in those with a history of GI bleeding or high risk of bleeding complications 1, 2) . Since PPIs are hepatic cytochrome P450 (CYP) 2C19 substrates and have potential negative effects on the therapeutic efficacy of clopidogrel 3, 4) , PPI agents with a weaker influence on CYP2C19 isoenzymes are preferred for co-administration with clopidogrel compared with those exhibiting stronger inhibition 1, 2) . Lansoprazole and omeprazole have been shown to have more potent inhibitory effects on the CYP2C19 activity than other PPIs 3) . In several studies, omeprazole has been found to consistently reduce the antiplatelet effects of clopidogrel [5] [6] [7] , and the Food Drug Administration recommends a cautioned approach for the co-administration of omeprazole and clopidogrel in patients at high risk for ischemic events. At the same time, pharmacokinetic and pharmacodynamic studies evaluating the interaction between the efficacy of lansoprazole and clopidogrel have shown inconsistent results 6, [8] [9] [10] [11] [12] . Furthermore, pharmacodynamic studies of patients with documented coronary artery disease have not demonstrated any significant interactions between lansoprazole and clopidogrel therapy 8, 11) . Cilostazol is a reversible dual inhibitor of adenosine uptake and phosphodiesterase 3 (PDE3), which induces an increase in the intraplatelet cyclic adenosine monophosphate (cAMP) levels and thus vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) 13, 14) . Cilostazol is widely used after cardiovascular intervention in Asian populations. In addition to its antiplatelet actions, cilostazol has been shown to have a beneficial effect on re-endothelialization, vasodilation, stem cell homing and inflammation in multiple translational studies. Furthermore, the addition of cilostazol to medication regimens in PCItreated patients has been shown to reduce major cardiovascular events, such as mortality, myocardial infarction and stent thrombosis 15) . In patients undergoing coronary stenting, combination therapy with cilostazol and aspirin has been reported to show similar efficacy in decreasing the incidence of ischemic events and reducing the risk of restenosis compared with standard antiplatelet therapy with clopidogrel and aspirin 16, 17) . Cilostazol inhibits both the primary and secondary platelet aggregation induced by collagen, adenosine diphosphate (ADP), arachidonic acid (AA) and epinephrine 13) . However, the different mechanism of (PGE1) alone, after which a second sample was incubated with PGE1＋10 μM ADP for 10 minutes. Both samples were fixed with paraformaldehyde. Platelets were then permeabilized using a non-ionic detergent and labeled with a primary monoclonal antibody against serine 239-phosphorylated VASP (16C2), followed by a secondary fluorescein isothiocyanate-conjugated polyclonal goat anti-mouse antibody. The final analyses were performed on a FC-500 Analyzer (Beckman Coulter Inc., Fullerton, California, USA). The platelet population was identified from its forward and side scatter distribution, and 10,000 platelet events were gated and analyzed for the mean fluorescence intensity (MFI). The platelet reactivity index (PRI) was calculated using the mean fluorescence intensity (MFI) measured in the presence of PGE1 alone (PGE1) and PGE1＋10 μM ADP (PGE1＋ADP) according to the following formula:
The absolute change in PRI (ΔPRI) was calculated as follows: ΔPRI = PRIfollow-up−PRIbaseline daily) in addition to lansoprazole co-administration (30 mg daily). No other changes in medications were permitted during the study period. At the 14±3 day follow-up visit, each patient's level of compliance and incidence of adverse events were assessed by the attending physician based on an interview, pill counting and questionnaire. If the patient showed complete compliance, blood samples for follow-up platelet function measurements were obtained two to six hours after the last study drug administration.
Platelet Function Assays
The blood samples were drawn into Vacutainer tubes containing 0.5 mL of sodium citrate 3.2% (Becton-Dickinson, San Jose, California). VASP-P assay and light transmittance aggregometry (LTA) were performed according to the previously published protocol 20) .
VASP-P Assay
This whole blood analysis was performed within eight hours of blood collection using Platelet VASP kits (BioCytex, Marseille, France). Briefly, the citrated blood sample was incubated with prostaglandin E1 
Sample Size Calculation and Statistical Analysis
Assuming a 25% relative difference in the VASP-PRI level at follow-up between the CLPD and CILO groups 18) , at least 44 patients were needed to demonstrate 95% power with a two-sided significance level of 0.05 (PS program version 3.0.14). With a 15% dropout rate among the enrolled patients, 51 patients were needed.
Continuous variables are expressed as the mean± SD, and categorical variables are expressed as percentages. The unpaired Student's t -test or Mann-Whitney U-test and ANOVA were used to compare continuous variables, while comparisons between categorical variables were made using the chi-square statistics or Fisher's exact test, as appropriate. If a variable showed a significant difference between the groups, a regression analysis was performed for adjusting. Comparisons of the platelet function between the values obtained at baseline and follow-up were made using the paired Student's t -test. The pharmacodynamic effects of different regimens were compared using a linear mixed model taking into account the within-subject correlation and a first-order autoregressive error structure. Each model included the treatment, time, interaction between treatment and time and the baseline pharmacodynamic parameters as covariates. Least squares (LS) estimates, which assess parameters by minimizing the squared discrepancies between the observed data and their expected values, of the mean difference are presented, with 95% confidence intervals (CIs) and a two-sided p value for the treatment effect. A multivariate linear regression model was employed to test for independent links of the demographic or genetic variables with the changes in the VASP-PRI level. Independent variables were chosen from genotypes and known variables with reported significant influence 21) . A p value of 0.05 was considered to be statistically significant, and the statistical analyses were performed using the SPSS v21.0 software package (SPSS Inc., Chicago, Illinois).
Results

Baseline Characteristics
Of the 104 patients enrolled, 100 completed the study protocol (two patients under cilostazol therapy discontinued the treatment due to the development of headaches and two patients dropped due to incomplete compliance) (Fig. 1) . No cardiovascular events or serious bleeding complications occurred during the study period. The baseline demographics were well matched between the groups ( Table 1) . Three-quarters of the patients were men. Approximately 60% of
Light Transmittance Aggregometry
Platelet aggregation was performed within two hours of blood sampling. Platelet-rich plasma (PRP) was obtained after centrifuging the blood samples at 120 g for 10 minutes. The remaining blood was further centrifuged at 1,200 g for 10 minutes to recover platelet-poor plasma (PPP). The PRP was adjusted to a platelet count of 250,000/mm 3 by adding PPP if needed. The 20 μM ADP-induced, 0.5 mg/mL AAinduced and 6 μg/mL collagen-induced platelet reactivity was evaluated for 10 minutes at 37℃ using an AggRAM aggregometer (Helena Laboratories Corp., Beaumont, Texas) by laboratory personnel blinded to the study protocol. The maximal (MPA) and final platelet aggregation at five minutes (FPA) were determined, and the absolute change in PA (ΔPA) was calculated as follows:
Genotyping
Genotyping was performed for CYP2C19 ＊ 2 (rs4244285, c.681G＞A) and ＊ 3 (rs4986893, c.636G ＞A), CYP3A5 ＊ 3 (rs776746, g.6986A＞G), ABCB1 C3435T (rs1045642) and paraoxonase-1 (PON-1) Q192R (rs662) alleles using a commercially available kit (QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany) after extracting genomic DNA from the whole blood leukocytes 21) . The genotypes were identified using the TaqMan method and a commercially available detection system (ABI PRISM 7900HT Sequence Detection System, Applied Biosystems). The polymerase chain reaction (PCR) amplification protocol for the TaqMan assays included denaturation at 95 ℃ for 10 minutes, followed by 40 cycles at 92 ℃ for 15 seconds, 60 ℃ for one minute and 72℃ for 45 seconds and elongation at 72 ℃ for five minutes. The TaqMan assay products were then read on a 7900HT Fast Real-Time PCR system. The patients were classified based on the number of single nucleotide polymorphisms of the evaluated genes.
Endpoints
The primary endpoint was VASP-PRI at followup. The secondary endpoints were 1) the 20 μM ADP-induced PA at follow-up; 2) the PAs after AA and collagen stimuli at follow-up; and 3) the differences in VASP-PRI and PAs between baseline and follow-up (ΔPRI and ΔPA). We also compared the platelet function measurements between the two groups according to the metabolic phenotype.
(56.9±16.5% vs. 60.4±16.4%; LS mean difference: −3.5%; 95% CI of difference: −10.0% to 3.0%; p = 0.289) ( Table 2) . After the 14-day administration period of the study drugs, the CLPD group showed similar values of VASP-PRI to those of the CILO group (66.9±14.0% vs. 63.1±14.1%; LS mean difference: 3.9%; 95% CI of difference: −1.7% to 9.4%; p = 0.174) (Fig. 2) .
Secondary Endpoint
The baseline values of the platelet aggregation measurements did not show any significant differences between the groups ( Table 2) . At the end of the treatment period, the 20 μM ADP-induced PA (MPA and the patients presented with previous myocardial infarction, and all patients were treated with drugeluting stents; standard cardiovascular medications were frequently used.
Genotyping was available in all 100 patients, and most of the alleles were in accordance with the HardyWeinberg equilibrium, except for the CYP3A5 ＊ 3 gene (Supplemental Table 1 ). As expected, the prevalence of CYP2C19 loss-of-function (LoF) allele carriage was high (60%).
Primary Endpoint
There were no differences in the baseline VASP-PRI values between the CLPD and CILO groups (25) 21 (21) 8 (8) 19 (19) 76 (76) 82 (82) 24 (24) 78 (78 (62) 1 (2) 24 (48) 12 (24) 12 (24) 3 (6) 9 (18) 38 (76) 40 (80) 15 (30) 40 (80 The values are expressed as the mean±SD, unless otherwise indicated. CRP = C-reactive protein; CVA = cerebrovascular accident; GFR = glomerular filtration rate; HbA1C = hemoglobin A1C; HDL = high-density lipoprotein; LDL = low-density lipoprotein; LV = left ventricular; MDRD = modification of diet in renal disease.
aspirin and cilostazol treatment during lansoprazole co-administration was associated with lower levels of collagen-and AA-induced PA (all p values ＜0.001), but not ADP-induced PA.
Pharmacodynamic Effects of the Treatments According to Metabolic Phenotype
Under aspirin and clopidogrel treatment without lansoprazole co-administration, there was a gene-dose dependent link between the number of CYP2C19 LoF allele(s) and the ADP-induced PA and VASP-PRI values (all p values ＜0.001), but not collagen-or AAinduced PA values (Supplemental Tables 2 to 5 ). In a FPA) values were similar between the two groups ( Table 2 and Fig. 2) . However, the 6 μg/mL collagenand 0.5 mg/mL AA-induced PA values in the CLPD group were higher than those observed in the CILO group (LS mean differences: 9.8% to 11.1%; all p values ＜0.001).
Adding lansoprazole to the aspirin and clopidogrel treatment regimen was associated with significantly greater levels of ADP-induced PA and VASP-PRI (ΔPRI, LS mean difference: 10.0%; 95% CI of difference: 5.7% to 14.3%; p＜0.001), but not collagen-or AA-induced PA (Table 2 and Fig. 3) . Compared with the baseline treatment, the addition of The values are expressed as the mean±SD, unless otherwise indicated. ＊ = p value between the CLPD vs. CILO group; ＊ ＊ = p value between baseline vs. follow-up treatment. ADP = adenosine diphosphate; CI = confidence interval; FPA = final platelet aggregation; LS = least square; LTA = light transmittance aggregometry; MPA = maximal platelet aggregation; PRI = platelet reactivity index; VASP-P = vasodilator-stimulated phosphoprotein phosphorylation.
patients treated with aspirin and cilostazol co-administered with lansoprazole (data not shown).
Discussion
This is the first study to demonstrate the pharmacodynamic effects of clopidogrel vs. cilostazol in stented patients under PPI co-administration. The findings of this study can be summarized as follows: 1) compared with clopidogrel treatment, cilostazol therapy showed similar ADP-induced PA values and lower AA-and collagen-induced PA values; 2) lansoprazole co-administration significantly attenuated only the ADP-induced PA values under clopidogrel and aspirin treatment, the effect of which disappeared in the patients carrying two CYP2C19 LoF alleles; and 3) CYP2C19 LoF ( ＊ 2 or ＊ 3) allele carriage (with the gene-dose effect) was a major contributing factor assomultivariate linear regression analysis, CYP2C19 LoF allele carriage was found to be independently associated with the level of VASP-PRI (β coefficient: 10.0%; 95% CI: 5.8% to 14.2%; p＜0.001) in a gene-dose fashion (1 and 2 LoF allele[s] carriage; β coefficient: 3.7% and 11.4%, respectively) ( Table 3) .
In the CLPD group, the addition of lansoprazole was associated with a trend towards a lower change in the VASP-PRI values across the CYP2C19 metabolic phenotypes (ΔPRI: 14.0±15.0%, 9.8±15.3% and 0.7±12.4% for carriers of 0, 1, and 2 LoF allele(s), respectively; p = 0.110). Consequently, CYP2C19 LoF allele carriage was not found to be associated with the VASP-PRI value during lansoprazole co-administration in a multivariate analysis (β coefficient: 2.9%; 95% CI: −4.8% to 10.5%; p = 0.450) ( Table 4) . Similarly, the VASP-PRI value did not exhibit any associations with the metabolic phenotype among the platelet inhibition compared with that achieved by doubling the clopidogrel dose in high-risk patients 23, 24) . These pharmacodynamic effects of TAPT are translated into a reduction in the incidence of adverse cardiovascular events without increasing the risk of serious bleeding in stented patients, compared with that observed in those receiving standard DAPT [25] [26] [27] . Furthermore, DAPT with aspirin and cilostazol has been found to be similarly effective and safe, when compared with clopidogrel, in preventing thrombotic complications after stenting, even in diabetic patients 16, 17) . The results of the present study are in line with those of the ACCEL-SWITCH (PhArmacodynamic effeC t of C lopidogrEL therapy and SWITCH ing to cilostazol in patients with the CYP2C19 loss-of-function allele) trial, which demonstrated that cilostazol treatment is associated with a lower AA/collageninduced platelet reactivity and similar degree of ADPinduced platelet reactivity as clopidogrel treatment 28) . Although there are no convincing data to date to clarify the mechanism underlying this observation, one ciated with the platelet function only in the absence of lansoprazole co-administration.
In Asian countries, cilostazol is used as antiplatelet treatment for diverse cardiovascular disease entities, including coronary artery disease, peripheral artery disease and stroke 13, 14) . Cilostazol is well known for its various actions in many cells. Cilostazol enhances the endothelial function by increasing the nitric oxide production, decreases various inflammatory responses in endothelial cells and improves the lipid profile. Cilostazol has also been shown to inhibit the expression of platelet activation markers, such as P-selectin and glycoprotein Ⅱb/Ⅲa receptors. Although cilostazol is not a platelet ADP P2Y12 receptor inhibitor, its unique antiplatelet effect cannot be ignored, as the ADP-stimulated platelet reactivity measured on platelet function testing has been shown to be associated with the occurrence of post-PCI ischemic events in numerous clinical studies 22) . The use of adjunctive cilostazol in addition to standard DAPT, triple antiplatelet therapy (TAPT), is associated with enhanced 50% of cilostazol's effects. OPC-13015 is primarily generated by CYP3A4, whereas OPC-13213 is predominantly generated by CYP2C19 19) . A decreased activity of CYP2C19 enzymes can increase the cilostazol and OPC-13015 plasma levels ("steal phenomenon"). For example, in one study, the co-administration of omeprazole with cilostazol resulted in an increase in the systemic exposure of cilostazol and OPC-13015 of 26% and 69%, respectively, with a decrease in OPC-13213 of 31%, thus implying the potentiated antiplatelet effects of cilostazol 33) . Aspirin causes gastric mucosal injury due to the underproduction of prostaglandin and subsequent attenuation of the mucosal blood flow 1) . In addition, aspirin induces direct local injury by disrupting the gastric mucosal barrier. On the other hand, clopidogrel does not have a direct effect on the gastric mucosa, but rather inhibits the healing process of gastric mucosal injury induced by aspirin. In contrast to that observed with aspirin and clopidogrel, several experimental studies have shown the beneficial effects of cilostazol on gastric mucosal damage and/or bleeding [34] [35] [36] [37] . Compared with aspirin, cilostazol significantly ameliorated microcirculatory and villous damage to the intestinal mucosa following ischemia-reperfusion injury in a mice study 34) . In other studies, cilostazol significantly reduced aspirin-and/or water-immersion plausible explanation is associated with the effects of the 'Akt pathway.' Akt is a key downstream molecule of phosphatidylinositol 3-kinase (PI3K) and is phosphorylated by several intraplatelet pathways, including those involving collagen and thromboxane. In animal experiments, cAMP elevation by cilostazol has been shown to inhibit collagen-induced Akt phosphorylation at Ser473 29) . In another crossover study, the addition of aspirin (325 mg daily) to cilostazol (100 mg twice a day) did not enhance the inhibition of AAinduced platelet aggregation compared with cilostazol alone (p = 0.38) 30) , implying the potential inhibition by cilostazol of thromboxane receptor-mediated platelet aggregation. Recent studies have also demonstrated that patients with high platelet reactivity (HPR) to multiple agonists are more susceptible to clinical events than those with HPR to any isolated agonists 31, 32) . Therefore, the pharmacodynamic effects and clinical benefits of adjunctive cilostazol may be underestimated when ADP is used as the sole platelet agonist to evaluate the platelet function.
Unlike clopidogrel, the administration of PPIs in addition to cilostazol is unlikely to influence the overall pharmacokinetics or pharmacodynamics of cilostazol 14) . Although, unlike clopidogrel, cilostazol is an active drug, two major metabolites of cilostazol (OPC-13015 and OPC13213) contribute to approximately Tables 1 and 2. lism in a competitive fashion. Despite the observation of a pharmacodynamic interaction between clopidogrel and PPI administration, the influence of this interaction on clinical outcomes associated with DAPT remains controversial 4) . Due to the similar GI protective effects of various PPIs, PPI drugs with a weaker inhibitory effect on CYP2C19 isoenzymes may be preferred in patients under clopidogrel treatment 1, 2) . The interaction between PPIs and clopidogrel may also depend on the potency of each PPI to inhibit CYP2C19. Only lansoprazole (K i: 0.4-1.5 μM) and omeprazole (K i: 2-6 μM) (and their S-enantiomers) are considered strong inhibitors based on the results of in vitro studies 3) . However, lansoprazole has been reported to exhibit a lower level of interaction with other CYP2C19 substrates compared with omeprazole 40) . Therefore, the irreversible (or quasi-irreversible) metabolism-dependent inhibition of CYP2C19 by omeprazole, not lansoprazole, may explain the effects of omeprazole on the pharmacodynamics of clopidogrel. A recent randomized, crossover study of healthy CYP2C19 ＊ 1/ ＊ 1 subjects (n = 160) also demonstrated that the effect of omeprazole on the plasma concentration and antiplatelet actions of clopidogrel appears to be greater than that of lansoprazole 6) . The results of the present study including stented patients highlight the significant interaction between lansoprazole and clopidogrel, although the observed stress-induced gastric mucosal inflammation and injury by suppressing the production of pro-inflammatory cytokines in rats 35, 36) . In contrast to aspirin and thienopyridine, cilostazol does not significantly prolong the bleeding time; this property remains even when cilostazol is added to other antiplatelet regimens 37) . In an observational study based on the findings of esophagogastroscopy (n = 755), thienopyridine and cilostazol administration resulted in a lower prevalence of mucosal injury than low-dose aspirin therapy 38) . However, the combination of cilostazol and aspirin also showed a similar risk of mucosal injury compared with combination treatment consisting of thienopyridine and aspirin (39.0% vs. 33.9%). Furthermore, safety concerns regarding cilostazol have recently been raised by the European Medicines Agency as a result of the increased incidence of adverse cardiovascular and hemorrhagic events associated with this drug 39) . Because safety concerns with respect to cilostazol have not been identified in the Asian populations in which this medication has been extensively used, the collection of large-scale confirmative data is warranted to evaluate the safety profile of cilostazol in terms of systemic and GI bleeding 13, 14, [25] [26] [27] . PPIs are often co-prescribed in patients in order to lessen the severity of GI bleeding associated with antiplatelet treatment. However, PPIs are metabolized by CYP2C19 and interact with clopidogrel metabo- The abbreviations are as in Table 3. for ischemic events is overestimated 44) . In addition, we previously reported that a value of "PRI＞~60%" exhibited a similar prevalence compared with the risk of HPR measured using other assays 20, 45) . Even after loading of 600 mg of clopidogrel in PCI-treated East Asians, the prevalence of HPR determined according to the VASP-P assay ("PRI＞50%") is 63.5% 20) . The latter observation may be related to the higher frequency of CYP2C19 LoF (tilting) allele carriage observed in East Asians compared with Caucasians (~65% vs. ~25%) 20, 45, 46) .
Limitations
Because the pharmacodynamic data for the CILO group obtained during the follow-up period may be influenced by the effects of both cilostazol and lansoprazole, the results of the present study cannot be used to conduct a direct comparison of data between clopidogrel and cilostazol in the stented patients. In addition, this study included only East Asians, and cilostazol has not been adequately tested in large-scale randomized clinical studies including Westerners 47) . Furthermore, the clinical impact of differences in the AA-or collagen-stimulated platelet function between clopidogrel and cilostazol has not yet been determined. Moreover, the enzyme activity of the studied genes may differ depending on gene variation or epigenetic factors, and the results of the present study should be considered in this context. The contribution of platelet reactivity to ischemic events appears to be weak in East Asians 48) .
Conclusions
In the present study, the concomitant use of lansoprazole reduced the antiplatelet effects of clopidogrel, but not aspirin, in the stented patients. During lansoprazole co-administration, cilostazol treatment results in similar levels of ADP-induced platelet aggregation and lower levels of arachidonic acid/collageninduced platelet aggregation compared with clopidogrel therapy. Therefore, the combination of cilostazol and aspirin may be a considerable maintenance regimen for stable stented patients under PPI co-administration, although further study is needed to support its clinical use. degree of pharmacodynamic interaction in CYP2C19 ＊ 1/ ＊ 1 carriers appeared to be greater in the current stented patients than in the healthy subjects (ΔVASP-PRI: 13.9% vs. 4.1%) 6) . Contrary to that observed in the healthy subjects, the baseline characteristics and concomitant medications used in the stented patients may have influenced the CYP2C19 enzyme activity. Moreover, Korean subjects carrying the CYP2C19 ＊ 1/ ＊ 1 gene exhibit lower CYP2C19 activity levels than Western subjects, which may make them more vulnerable to the influence of PPI co-administration 41) . The present study also suggests that the negative influence of PPI co-administration on the antiplatelet effect of clopidogrel may differ according to the CYP2C19 phenotype. In the patients with 2 CYP2C19 LoF alleles (poor metabolizers), the coadministration of a PPI did not affect the pharmacodynamic effect of clopidogrel. We therefore propose that the LoF effect of the CYP2C19 ＊ 2 or ＊ 3 allele may be greater than that of PPI co-administration, implying the almost complete loss of enzyme activity as a result of the CYP2C19 LoF mutation. Therefore, a simple additive estimation of the negative effects of the CYP2C19 LoF allele and PPI co-administration on the efficacy of clopidogrel may not properly reflect the true clinical influence.
PPI co-administration may also interact with the antiplatelet effects of aspirin by reducing gastric acidity, thereby inhibiting the uptake of the weakly acidic aspirin 2) . Recently, it was reported that the concomitant use of PPIs reduces the antiplatelet effect and protective clinical efficacy of aspirin in patients with coronary artery disease based on the findings of casecontrol studies 42, 43) . However, the interaction between PPI and aspirin therapy remains controversial. The results of the present study suggest that lansoprazole therapy does not influence the antiplatelet effect of aspirin (as measured by the AA-and collagen-induced PA values). Among aspirin-treated patients, those coadministered a PPI may have worse baseline characteristics, along with concomitant GI disorders 2) . Even after conducting propensity score matching analyses, unrecognized confounding factors cannot be excluded in the absence of randomized controlled trials.
In the present study, the PRI values and risk of HPR ("PRI＞50%") 22) in the patients taking standard-dose clopidogrel seemed very high. However, the higher prevalence of HPR among the clopidogreltreated patients determined by the VASP-P assay, as compared with the findings of other assays performed under clopidogrel therapy (＞50% vs. 20-40%), raises the question whether "PRI＞50%" may be too low, such that the true proportion of patients at high risk ＊ ＊ = p value between baseline vs. follow-up treatment. ADP = adenosine diphosphate; CYP = cytochrome P450; FPA = final platelet aggregation; LTA = light transmittance aggregometry; MPA = maximal platelet aggregation; PRI = platelet reactivity index; VASP-P = vasodilator-stimulated phosphoprotein phosphorylation.
